{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:06:54Z","timestamp":1791421614448,"version":"4.3.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, which leads to visual impairment in a large proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual loss by controlling infection and inflammation. However, there remains disagreement regarding optimal antibiotic therapy for OT. Therefore,\u00a0this systematic review and meta-analysis were performed to determine the effects and safety of existing antibiotic treatment regimens for OT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials, LILACS, WHO International Clinical Trials Registry Platform portal, ClinicalTrials.gov, and Gray Literature in Europe (\u201cOpenGrey\u201d) were searched for relevant studies; manual searches of reference lists were performed for studies identified by other methods. All published and unpublished randomized controlled trials that compared antibiotic schemes known to be effective in OT at any dosage, duration, and administration route were included. Studies comparing antibiotics with placebo were excluded. This review followed standard methodological procedures recommended by the Cochrane group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten studies were included in the narrative summary, of which four were included for quantitative synthesis (meta-analysis). Interventions were organized into three groups: intravitreal clindamycin versus\u00a0pyrimethamine\u2009+\u2009sulfadiazine, trimethoprim\u2009+\u2009sulfamethoxazole versus other antibiotics, and other interventions. The first comparison favored intravitreal clindamycin (Mean difference\u00a0(MD)\u2009=\u20090.10 logMAR; 95% confidence interval\u2009=\u20090.01 to 0.22). However, this finding lacks clinical relevance. Other outcomes showed no statistically significant differences between the treatment groups. In general, the risk of performance bias was high in evaluated studies, and the quality of the evidence found was low to very low.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No antibiotic scheme was superior to others, and the selection of a treatment regimen depends on multiple factors; therefore, treatment should be chosen based on safety, sulfa allergies, and availability.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13643-021-01758-7","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T01:02:31Z","timestamp":1626656551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis"],"prefix":"10.1186","volume":"10","author":[{"given":"John E.","family":"Feliciano-Alfonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Mu\u00f1oz-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Alejandra","family":"Mar\u00edn-Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Vargas-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Trivi\u00f1o-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Carvajal-Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"1758_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.iio.0000155938.83083.94","volume":"45","author":"D Wakefield","year":"2005","unstructured":"Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1\u201313.","journal-title":"Int Ophthalmol Clin"},{"key":"1758_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/09273948.2017.1367407","volume":"26","author":"PK Huang","year":"2018","unstructured":"Huang PK, Jianping C, Vasconcelos-Santos DV, Arruda JSD, Dutta Majumder P, Anthony E, et al. Ocular toxoplasmosis in tropical areas: analysis and outcome of 190 patients from a multicenter collaborative study. Ocul Immunol Inflamm. 2018;26:1289\u201396.","journal-title":"Ocul Immunol Inflamm"},{"key":"1758_CR3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","volume":"363","author":"J Montoya","year":"2004","unstructured":"Montoya J, Liesenfeld O. Toxoplasmosis The lancet. 2004;363:1965\u201376.","journal-title":"Toxoplasmosis The lancet"},{"key":"1758_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ijpara.2009.04.003","volume":"39","author":"G Pappas","year":"2009","unstructured":"Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39:1385\u201394.","journal-title":"Int J Parasitol"},{"key":"1758_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.parint.2018.07.004","volume":"67","author":"K Khan","year":"2018","unstructured":"Khan K, Khan W. Congenital toxoplasmosis: An overview of the neurological and ocular manifestations. Parasitol Int. 2018;67:715\u201321.","journal-title":"Parasitol Int"},{"key":"1758_CR6","doi-asserted-by":"crossref","unstructured":"Laurence Baril BC Thierry Ancelle, V\u00e9ronique Goulet, Philippe Thulliez, V\u00e9ronique Tirard-Fleury. Risk Factors for Toxoplasma Infection in Pregnancy: A Case-Control Study in France. Scand J Infect Dis. 1999;31:305\u20139.","DOI":"10.1080\/00365549950163626"},{"key":"1758_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/cir806","volume":"54","author":"N Fern\u00e0ndez-Sab\u00e9","year":"2012","unstructured":"Fern\u00e0ndez-Sab\u00e9 N, Cervera C, Fari\u00f1as MC, Bodro M, Mu\u00f1oz P, Gurgu\u00ed M, et al. Risk Factors, Clinical Features, and Outcomes of Toxoplasmosis in Solid-Organ Transplant Recipients: A Matched Case-Control Study. Clin Infect Dis. 2012;54:355\u201361.","journal-title":"Clin Infect Dis"},{"key":"1758_CR8","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1542\/peds.2013-2153","volume":"133","author":"M Wallon","year":"2014","unstructured":"Wallon M, Garweg JG, Abrahamowicz M, Cornu C, Vinault S, Quantin C, et al. Ophthalmic Outcomes of Congenital Toxoplasmosis Followed Until Adolescence. Pediatrics. 2014;133:e601\u20138.","journal-title":"Pediatrics"},{"key":"1758_CR9","doi-asserted-by":"crossref","unstructured":"Oz HS, Tobin T. Atovaquone ameliorate gastrointestinal Toxoplasmosis complications in a pregnancy model. Med Sci Monit Int Med J Exp Clin Res. 2012;18:BR337\u201345.","DOI":"10.12659\/MSM.883342"},{"key":"1758_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/CMR.05013-11","volume":"25","author":"F Robert-Gangneux","year":"2012","unstructured":"Robert-Gangneux F, Dard\u00e9 M-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25:264\u201396.","journal-title":"Clin Microbiol Rev"},{"key":"1758_CR11","first-page":"10","volume":"17","author":"EM Dodds","year":"1999","unstructured":"Dodds EM. Ocular toxoplasmosis: Clinical presentation, diagnosis and therapy. Focal Points Clin Modul Ophthalmol. 1999;17:10.","journal-title":"Focal Points Clin Modul Ophthalmol"},{"key":"1758_CR12","unstructured":"Casoy J, Nascimento H, Silva LMP, Fern\u00e1ndez-Zamora Y, Muccioli C, Dias JR de O, et al. Effectiveness of Treatments for Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2019;1\u20137."},{"key":"1758_CR13","doi-asserted-by":"crossref","unstructured":"Pradhan E, Bhandari S, Gilbert RE, Stanford M. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev. 2016;CD002218.","DOI":"10.1002\/14651858.CD002218.pub2"},{"key":"1758_CR14","doi-asserted-by":"publisher","unstructured":"Vasconcelos-Santos DV. Ocular Toxoplasmosis. In: Dumitrescu RG, Verma M, editors. Cancer Epigenetics Precis Med [Internet]. New York, NY: Springer New York; 2019 [cited 2019 Apr 7]. p. 79\u201397. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-030-03140-4_5","DOI":"10.1007\/978-3-030-03140-4_5"},{"key":"1758_CR15","doi-asserted-by":"crossref","unstructured":"de-la-Torre A, Stanford M, Curi A, Jaffe GJ, Gomez-Marin JE. Therapy for Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2011;19:314\u201320.","DOI":"10.3109\/09273948.2011.608915"},{"key":"1758_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ajo.2005.04.048","volume":"140","author":"F Lum","year":"2005","unstructured":"Lum F, Jones JL, Holland GN, Liesegang TJ. Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol. 2005;140:724-e1.","journal-title":"Am J Ophthalmol"},{"key":"1758_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/QCO.0000000000000577","volume":"32","author":"JA Cort\u00e9s","year":"2019","unstructured":"Cort\u00e9s JA, Roncancio \u00c1, Uribe LG, Cort\u00e9s-Luna CF, Montoya JG. Approach to ocular toxoplasmosis including pregnant women. Curr Opin Infect Dis. 2019;32:426\u201334.","journal-title":"Curr Opin Infect Dis"},{"key":"1758_CR18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0161-6420(03)00083-6","volume":"110","author":"MR Stanford","year":"2003","unstructured":"Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology. 2003;110:926\u201332.","journal-title":"Ophthalmology"},{"key":"1758_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.actatropica.2018.04.026","volume":"185","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Lin X, Lu F. Current treatment of ocular toxoplasmosis in immunocompetent patients: A network meta-analysis. Acta Trop. 2018;185:52\u201362.","journal-title":"Acta Trop"},{"key":"1758_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"1758_CR21","doi-asserted-by":"crossref","unstructured":"Feliciano-Alfonso JE, Vargas-Villanueva A, Mu\u00f1oz-Ortiz J, de-la-Torre A. Antibiotic treatment for ocular toxoplasmosis: a systematic review and meta-analysis: study protocol. Syst Rev [Internet]. 2019;8:146\u2013146. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31221217","DOI":"10.1186\/s13643-019-1067-8"},{"key":"1758_CR22","unstructured":"PROSPERO: International prospective register of systematic reviews [Internet]. [cited 2020 Nov 26]. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=85468"},{"key":"1758_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(16)31592-6","volume":"390","author":"B Djulbegovic","year":"2017","unstructured":"Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. The Lancet. 2017;390:415\u201323.","journal-title":"The Lancet"},{"key":"1758_CR24","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"GRADE Working Group","year":"2004","unstructured":"GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.","journal-title":"BMJ"},{"key":"1758_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/09273948.2011.547157","volume":"19","author":"D Wakefield","year":"2011","unstructured":"Wakefield D, Cunningham ET Jr, Pavesio C, Garweg JG, Zierhut M. Controversies in ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19:2\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"1758_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0002-9394(14)73706-7","volume":"111","author":"RE Engstrom Jr","year":"1991","unstructured":"Engstrom RE Jr, Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111:601\u201310.","journal-title":"Am J Ophthalmol"},{"key":"1758_CR27","doi-asserted-by":"crossref","unstructured":"Gilbert RE, Harden M, Stanford M. Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database Syst Rev. 2002;","DOI":"10.1002\/14651858.CD002218"},{"key":"1758_CR28","doi-asserted-by":"crossref","unstructured":"Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis1, 2. Elsevier; 2002.","DOI":"10.1016\/S0002-9394(02)01526-X"},{"key":"1758_CR29","unstructured":"Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. Www Cochrane-Handb Org. 2011;"},{"key":"1758_CR30","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.ophtha.2005.05.025","volume":"112","author":"M Soheilian","year":"2005","unstructured":"Soheilian M, Sadoughi M-M, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H, et al. Prospective randomized trial of trimethoprim\/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112:1876\u201382.","journal-title":"Ophthalmology"},{"key":"1758_CR31","first-page":"26","volume":"51","author":"M Abreu","year":"1988","unstructured":"Abreu M, Martins M, Belfort R. Clindamycin versus spiramycin in ocular toxoplasmosis: a randomised double masked study. Arq Bras Oftalmol. 1988;51:26.","journal-title":"Arq Bras Oftalmol"},{"key":"1758_CR32","first-page":"418","volume":"20","author":"A Jeddi","year":"1997","unstructured":"Jeddi A, Azaiez A, Bouguila H, Kaoueche M, Malouche S, Daghfous F, et al. Value of clindamycin in the treatment of ocular toxoplasmosis. J Fr Ophtalmol. 1997;20:418.","journal-title":"J Fr Ophtalmol"},{"key":"1758_CR33","first-page":"112","volume":"20","author":"P Prasil","year":"2014","unstructured":"Prasil P, Plisek S. Bostik P [Ocular toxoplasmosis - seeking a strategy for treatment]. Klin Mikrobiol Infekcni Lek. 2014;20:112\u20135.","journal-title":"Klin Mikrobiol Infekcni Lek"},{"key":"1758_CR34","first-page":"335","volume":"61","author":"E Raskin","year":"2002","unstructured":"Raskin E, Alves M, Eredia G, Raskin A, Ruiz AM. Ocular toxoplasmosis: A comparative study of the treatment with sulfadiazine and pyrimetamine versus sulphametoxazole-trimethoprim. Rev Bras Oftalmol. 2002;61:335\u20138.","journal-title":"Rev Bras Oftalmol"},{"key":"1758_CR35","unstructured":"Sadoughi M-M, SOHEYLIAN M, Dehghan M-H, Behboudi H, Anisian A, Yazdani S. Short-term results of two treatment regimens in ocular toxoplasmosis: Trimethoprim\/sulfamethoxazole versus pyrimethamine and sulfadiazine. 2006;"},{"key":"1758_CR36","doi-asserted-by":"crossref","unstructured":"Balaskas K, Vaudaux J, Boillat-Blanco N, Guex-Crosier Y. Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit Int Med J Exp Clin Res. 2012;18:CR296.","DOI":"10.12659\/MSM.882735"},{"key":"1758_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10792-012-9634-1","volume":"33","author":"N Baharivand","year":"2013","unstructured":"Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol. 2013;33:39\u201346.","journal-title":"Int Ophthalmol"},{"key":"1758_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0002-9394(02)01537-4","volume":"134","author":"LH Bosch-Driessen","year":"2002","unstructured":"Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:34\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1758_CR39","first-page":"161","volume":"12","author":"J Colin","year":"1989","unstructured":"Colin J, Harie J. Presumed toxoplasmic chorioretinitis: comparative study of treatment with pyrimethamine and sulfadiazine or clindamycin. J Fr Ophtalmol. 1989;12:161\u20135.","journal-title":"J Fr Ophtalmol"},{"key":"1758_CR40","first-page":"80","volume":"4","author":"LA Ghavidel","year":"2017","unstructured":"Ghavidel LA, Milani AE, Bagheri M. Comparison of azithromycin and pyrimethamine\/sulfadiazine treatment in ocular toxoplasmosis in North West of Iran. Crescent J Med Biol Sci. 2017;4:80\u20134.","journal-title":"Crescent J Med Biol Sci"},{"key":"1758_CR41","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2147\/OPTH.S148933","volume":"11","author":"A Kartasasmita","year":"2017","unstructured":"Kartasasmita A, Muntur WP, Enus S, Iskandar E. Rapid resolution of toxoplasma chorioretinitis treatment using quadruple therapy. Clin Ophthalmol Auckl NZ. 2017;11:2133.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"1758_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.joco.2016.10.002","volume":"29","author":"A Lashay","year":"2017","unstructured":"Lashay A, Mirshahi A, Parandin N, Riazi Esfahani H, Mazloumi M, Reza Lashay M, et al. A prospective randomized trial of azithromycin versus trimethoprim\/sulfamethoxazole in treatment of toxoplasmic retinochoroiditis. J Curr Ophthalmol. 2017;29:120\u20135.","journal-title":"J Curr Ophthalmol"},{"key":"1758_CR43","first-page":"5","volume":"74","author":"G Ortega Larrocea","year":"2000","unstructured":"Ortega Larrocea G, Becerril Galindo M, Navarro Montes A, Arellanes GL. Clindamicina vs pirimetamina en el tratamiento de la toxoplasmosis ocular activa. Rev Mex Oftalmol. 2000;74:5\u201310.","journal-title":"Rev Mex Oftalmol"},{"key":"1758_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ophtha.2010.04.020","volume":"118","author":"M Soheilian","year":"2011","unstructured":"Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118:134\u201341.","journal-title":"Ophthalmology"},{"key":"1758_CR45","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","volume":"114","author":"RW Beck","year":"2007","unstructured":"Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804\u20139.","journal-title":"Ophthalmology"},{"key":"1758_CR46","unstructured":"Ana Mart\u00ednez Rubioj JGA. Valoraci\u00f3n de la agudeza visual [Internet]. Rev Pediatr Aten Primaria Vol18 No71 Madr. Julsep 2016. 2016 [cited 2019 Aug 19]. Available from: http:\/\/scielo.isciii.es\/pdf\/pap\/v18n71\/1139-7632-pap-18-71-00267.pdf"},{"key":"1758_CR47","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ajo.2013.12.022","volume":"157","author":"JPF Felix","year":"2014","unstructured":"Felix JPF, Lira RPC, Zacchia RS, Toribio JM, Nascimento MA, Arieta CEL. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am J Ophthalmol. 2014;157:762\u20136.","journal-title":"Am J Ophthalmol"},{"key":"1758_CR48","doi-asserted-by":"crossref","unstructured":"Vishnevskia-Dai V, Achiron A, Buhbut O, Berar OV, Musika AA, Elyashiv SM, et al. Chorio-retinal toxoplasmosis: treatment outcomes, lesion evolution and long-term follow-up in a single tertiary center. Int Ophthalmol. 2019;1\u201311.","DOI":"10.1007\/s10792-019-01242-1"},{"key":"1758_CR49","doi-asserted-by":"crossref","unstructured":"Group S of UN (SUN) W. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509\u2013516.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"1758_CR50","doi-asserted-by":"crossref","unstructured":"Borkowski PK, Brydak-Godowska J, Basiak W, Switaj K, Zarnowska-Prymek H, Olszynska-Krowicka M, et al. The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence. PLoS Negl Trop Dis. 2016;10:e0004892.","DOI":"10.1371\/journal.pntd.0004892"},{"key":"1758_CR51","doi-asserted-by":"crossref","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. bmj. 2017;358:j4008.","DOI":"10.1136\/bmj.j4008"},{"key":"1758_CR52","unstructured":"Using the AMSTAR checklist for network meta-analysis: does it fit? | The 24th Cochrane Colloquium [Internet]. [cited 2020 Jan 28]. Available from: http:\/\/2016.colloquium.cochrane.org\/abstracts\/using-amstar-checklist-network-meta-analysis-does-it-fit"},{"key":"1758_CR53","doi-asserted-by":"crossref","unstructured":"Nikolakopoulou A, Higgins JP, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17:e1003082.","DOI":"10.1371\/journal.pmed.1003082"},{"key":"1758_CR54","doi-asserted-by":"crossref","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JP, Egger M, Salanti G. CINeMA: Software for semiautomated assessment of the confidence in the results of network meta\u2010analysis. Campbell Syst Rev. 2020;16:e1080.","DOI":"10.1002\/cl2.1080"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-021-01758-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-021-01758-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-021-01758-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T20:52:35Z","timestamp":1672865555000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-021-01758-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1758"],"URL":"https:\/\/doi.org\/10.1186\/s13643-021-01758-7","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"6 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}